Related Experiment Video
Updated: Jun 21, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic
Sophie A Jamal1, David Fitchett, Charmaine E Lok
1University of Toronto, Division of Endocrinology and Metabolism, Women's College Hospital, Toronto, Canada.
Insights
Non-calcium phosphate binders showed a trend toward lower mortality in chronic kidney disease patients. However, significant differences in cardiovascular events or vascular calcification were not found, necessitating further research.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Pharmacology
Background:
- The comparative effects of calcium-based versus non-calcium-based phosphate binders on patient outcomes in chronic kidney disease (CKD) remain unclear.
- Key outcomes of interest include mortality, cardiovascular events, and vascular calcification.
Purpose of the Study:
- To systematically review and analyze the available evidence comparing calcium-based and non-calcium-based phosphate binders in CKD patients.
- To assess the impact of these binders on mortality, cardiovascular events, and vascular calcification.
Main Methods:
- A systematic review was performed using electronic searches of major biomedical databases (MEDLINE, EMBASE, Cochrane, CINAHL).
- Included were 8 randomized trials involving 2873 patients, identified through predefined criteria.
- Data extraction and analysis were conducted systematically.
Main Results:
- A trend towards decreased all-cause mortality was observed with non-calcium-based binders (RR 0.68; 95% CI 0.41-1.11).
- No statistically significant difference was found for cardiovascular events (RR 0.85; 95% CI 0.35-2.03).
- Analysis of coronary artery calcification showed a non-significant trend favoring non-calcium-based binders (change in calcium score: -76.35; 95% CI -158.25-5.55).
Conclusions:
- While trends suggest potential benefits of non-calcium-based phosphate binders, statistically significant differences were not established for mortality, cardiovascular events, or coronary artery calcification.
- The current evidence is limited by the small number of studies and sample sizes.
- Further randomized trials are warranted to definitively assess the comparative efficacy and safety of these agents.
Background:
The effects of calcium compared with non-calcium-based phosphate binders on mortality, cardiovascular events and vascular calcification in patients with chronic kidney disease (CKD) are unknown.
Methods:
To address this question, we conducted a systematic review. We electronically searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and CINAHL. We identified 160 potential studies and included 8 randomized trials. Eligible studies, determined by consensus using predefined criteria, were reviewed, and data were extracted onto a standard from.
Results:
There was a trend towards a decrease in all-cause mortality among non-calcium-based versus calcium-based phosphate binders [relative risk (RR) 0.68; 95% CI 0.41-1.11] based upon eight randomized controlled trials and 2873 subjects. Two trials reported on cardiovascular events with a RR of 0.85 (95% CI 0.35-2.03) in patients receiving calcium-based versus non-calcium-based binders. Coronary artery calcification was reported in five trials involving 469 patients; the difference in the change in the calcium score from baseline to follow-up among subjects taking non-calcium-based binders versus calcium-based binders was -76.35 (95% CI -158.25-5.55).
Conclusion:
Despite the trends observed, we did not find a statistically significant difference in cardiovascular mortality and coronary artery calcification in patients receiving calcium-based phosphate binders compared to non-calcium-based phosphate binders. However, the data are limited by the small number of studies and the confidence intervals do not exclude a potentially important beneficial effect. Therefore, further randomized trials are required.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Skeleton and Calcium Homeostasis
Chronic Kidney Disease IV: Nursing Management
Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and case-control studies.
